Navigation Links
Multicenter study confirms low testosterone in 84 percent of lung cancer patients taking crizotinib
Date:4/16/2013

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib. A new study published this week in the journal Cancer confirms this finding in a multi-national sample, details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can alleviate this side effect in many patients.

"This was a wonderful collaboration between multiple centers confirming a side effect that had not been noted when the drug was initially approved by the FDA," says Ross Camidge, MD, PhD, investigator at the CU Cancer Center, director of the thoracic oncology clinical program at University of Colorado Hospital, and the paper's senior author.

Specifically, the study which included researchers in the United States, Hong Kong, Italy and the UK found that in 84 percent of men treated with crizotinib, testosterone levels were below the lower limit of normal. Importantly, this study also showed, for the first time, that approximately 80 percent of these men had symptoms associated with their low testosterone such as sexual dysfunction or depression.

Testosterone levels seemed to fall for two main reasons. First, the proteins albumin and SHBG that bind testosterone in the blood and act as a storage depot for the hormone dropped rapidly with crizotinib use. Additionally, free testosterone the functional form of the hormone that is liberated from these proteins was also reduced, implying that in addition to challenging the body's ability to store testosterone, crizotinib also challenges the body's ability to produce it. Camidge and colleagues went on to show that when low levels are found, testosterone replacement therapy may alleviate these symptoms.

"With advances in targeted therapies and in the biomarkers we can use to select who to best give these new treatments to, we're starting to see drugs being approved more quickly and based on the results from far smaller numbers of patients than ever before. That's great: it helps streamline the path of these drugs into clinics where they can benefit patients who desperately need them. However, it also puts the onus on clinicians who then start using these drugs in day-to-day practice to recognize either subtle or later onset side effects that may have been missed during the initial testing," Camidge says.

For example, he says, it's perhaps not surprising that the potential for lowered testosterone was overlooked during the lightning-fast approval process for crizotinib: "If you don't specifically ask a man about symptoms of low testosterone, unless you know the patient very well, he may not feel comfortable bringing these issues up himself," Camidge says.

Now with the possibility of low testosterone in mind, clinicians who prescribe crizotinib to their male patients will know to ask about these symptoms and to test their testosterone levels. "With each breakthrough we're really trying to put people with advanced cancer back in control of their own lives," says Camidge. "The more we can make these highly effective new treatments tolerable, the closer we are to achieving that goal."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Results released for first multicenter study of hybrid revascularization
2. Heart Scarring May Be More Dangerous Than Thought, Study Suggests
3. Colic May Be Linked to Childhood Migraine, Study Says
4. New study finds digoxin safe despite recent reports
5. Babies Born Even Slightly Early May Lag Behind: Study
6. Study May Explain How Circumcision Reduces HIV Risk
7. New Study Links Air Pollution to Alzheimer’s Disease -- Says Cure Alzheimer's Fund
8. Study Questions Value of PSA Test for Older Men
9. Doctors Insight Into Patients Lives May Boost Care, Study Finds
10. Drug could improve working memory of people with autism, study finds
11. Freezing Treatment May Help Destroy Lung Tumors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on his ... the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family ... hospital’s 30th heart transplant recipient. , “He was playing at home, when we got ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to ... fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife ... children of the world. , In exchange for generous donations, customers will receive a ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, ... medicines company, announced today that it entered into ... RNA-based therapeutics for the treatment of NASH and ... therapeutic delivery platform LUNAR™ and UNA Oligomer chemistry. ... "Given Takeda,s long-standing commitment to and expertise in ...
(Date:12/6/2016)... 2016  Regulus Therapeutics Inc. (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... R&D day, held in New York ... anti-miR targeting microRNA-27 (miR-27) for the treatment of ... anti-miR targeting microRNA-17 (miR-17) for the treatment of ...
(Date:12/6/2016)... A new study released today by the ... the 340B Drug Pricing Program will continue to expand at ... expected to exceed $23 billion in total purchases at the ... current Medicare Part B drug reimbursement purchases over the next ... on analysis of data on total drug purchases through 340B ...
Breaking Medicine Technology: